Anticoagulation Resumption After Intracerebral Hemorrhage

Yan-guang Li, Gregory Y. H. Lip

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)
174 Downloads (Pure)


Purpose of review Decision-making on resuming oral anticoagulant (OAC) after intracerebral hemorrhage (ICH) evokes significant debate among clinicians. Such patients have been excluded from randomized clinical trials. This review article provides a comprehensive summary of the evidence on anticoagulation resumption after ICH. Recent findings OAC resumption does not increase the risk of recurrent ICH and can also reduce the risk of all-cause mortality. OAC cessation exposes patients to a significantly higher risk of thromboembolism, which could be reduced by resumption. The optimal timing of anticoagulation resumption after ICH is still unknown. Both early (< 2 weeks) and late (> 4 weeks) resumption should be reached only after very careful assessment of risks for ICH recurrence and thromboembolism. The introduction of new oral anticoagulants and other interventions, such as left atrial appendage closure, has provided some patients with more alternatives. Summary Given the lack of high-quality evidence to guide clinical decision-making, clinicians must carefully balance the risks of thromboembolism and recurrent ICH in individual patients. We propose a management approach which would facilitate the decision-making process on whether anticoagulation is appropriate, as well as when and how to restart anticoagulation after ICH.
Original languageEnglish
Article number32
JournalCurrent Atheroscler Reports
Issue number7
Early online date21 May 2018
Publication statusPublished - 1 Jul 2018


Dive into the research topics of 'Anticoagulation Resumption After Intracerebral Hemorrhage'. Together they form a unique fingerprint.

Cite this